{
    "hands_on_practices": [
        {
            "introduction": "The synapse is the fundamental computational unit of the nervous system, and its strength determines the flow of information. This exercise grounds you in the quantal theory of neurotransmission by challenging you to work backward from simulated experimental data to deduce a synapse's core parameters: the number of release sites ($N$), the probability of release ($p$), and the quantal size ($q$). Mastering this approach provides a quantitative framework for understanding synaptic function and plasticity.",
            "id": "4731575",
            "problem": "A layer 2/3 cortical pyramidal neuron is recorded in whole-cell voltage clamp at a holding potential of $-70\\,\\text{mV}$. Minimal extracellular stimulation is used to activate a putative single excitatory synaptic input. Across $160$ stimulation trials delivered at $0.1\\,\\text{Hz}$ in normal extracellular calcium, the following are measured from the peak excitatory postsynaptic current (EPSC) within a fixed post-stimulus window, using all trials including failures:\n- The across-trial mean evoked EPSC amplitude is $20\\,\\text{pA}$.\n- The across-trial variance of the evoked EPSC amplitude is $104\\,\\text{pA}^2$.\n- Exactly $10$ trials are failures (no detectable evoked response above baseline).\n\nIndependent baseline recordings without stimulation yield a pre-stimulus noise variance of $4\\,\\text{pA}^2$ measured over identically sized time windows. In a separate set of trials in strontium-substituted extracellular solution, asynchronous quantal events time-locked to the same stimulation are collected from the same connection. These asynchronous events have a mean amplitude of $10\\,\\text{pA}$ with a narrow distribution that can be treated as effectively constant at the mean for the purpose of modeling.\n\nModel the synapse as $N$ independent, identical release sites, each undergoing a Bernoulli release event per trial with probability $p$, and each successful release producing a postsynaptic current of fixed quantal size $q$. Assume linear summation of quantal currents, negligible receptor saturation and desensitization over the measurement window, and additive, independent baseline noise with the measured noise variance. Starting only from basic properties of independent Bernoulli trials and linearity of expectation and variance, derive expressions that relate the measurable across-trial mean evoked EPSC amplitude, the failure fraction, and the across-trial variance of the evoked EPSC amplitude to $N$, $p$, and $q$. Then use the provided data to estimate $N$, $p$, and $q$. Finally, use the variance data to numerically assess whether the binomial quantal model is consistent with the measurements under the stated assumptions.\n\nReport the final numerical estimates in the order $N$, $p$, $q$. Express $q$ in picoamperes. Do not include any units in your final boxed answer. No rounding is required.",
            "solution": "The problem is first assessed for validity.\n\n**Step 1: Extract Givens**\n- Total number of stimulation trials, $M$: $160$\n- Holding potential: $-70\\,\\text{mV}$\n- Stimulation frequency: $0.1\\,\\text{Hz}$\n- Mean evoked Excitatory Postsynaptic Current (EPSC) amplitude, $\\mu_{EPSC}$: $20\\,\\text{pA}$\n- Variance of the evoked EPSC amplitude, $\\sigma^2_{EPSC}$: $104\\,\\text{pA}^2$\n- Number of failures (zero-response trials), $n_{fail}$: $10$\n- Pre-stimulus baseline noise variance, $\\sigma^2_{noise}$: $4\\,\\text{pA}^2$\n- Mean asynchronous quantal event amplitude, $q_{async}$: $10\\,\\text{pA}$\n- Model: A synapse with $N$ independent and identical release sites. Each site releases a quantum of neurotransmitter with probability $p$ upon stimulation (a Bernoulli trial). Each successfully released quantum generates a postsynaptic current of fixed size $q$.\n- Assumptions: Linear summation of quantal currents, additive and independent baseline noise, negligible receptor saturation and desensitization.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, being a standard application of the binomial model of synaptic transmission, a foundational concept in neurophysiology. The experimental parameters and measured values are within a physiologically realistic range for a cortical synapse. The problem is well-posed, providing sufficient data ($3$ measurements: mean, variance, failure rate) to estimate the $3$ model parameters ($N$, $p$, $q$). The language is objective and precise. The problem does not exhibit any flaws such as scientific unsoundness, incompleteness, contradiction, or ambiguity.\n\n**Step 3: Verdict and Action**\nThe problem is determined to be **valid**. A full solution is warranted.\n\n**Derivation of Model Equations**\n\nWe model the synaptic response based on the provided binomial framework. Let $k$ be the number of quanta released in a single trial. Since there are $N$ independent release sites, each with a release probability $p$, the random variable $k$ follows a binomial distribution, $k \\sim B(N,p)$. The probability of observing exactly $k$ releases is given by:\n$$P(k) = \\binom{N}{k} p^k (1-p)^{N-k}$$\nThe total measured current in a trial, $I$, is the sum of the synaptic current, $I_{syn} = kq$, and the additive baseline noise, $I_{noise}$.\n$$I = I_{syn} + I_{noise} = kq + I_{noise}$$\nWe assume the noise has zero mean, $E[I_{noise}] = 0$, and a variance of $\\sigma^2_{noise}$. The synaptic current and noise are assumed to be independent.\n\n1.  **Mean Evoked EPSC Amplitude ($\\mu_{EPSC}$)**:\n    By linearity of expectation, the mean of the total measured current is:\n    $$\\mu_{EPSC} = E[I] = E[kq + I_{noise}] = E[kq] + E[I_{noise}]$$\n    Since $q$ is a constant and $E[I_{noise}] = 0$:\n    $$\\mu_{EPSC} = q E[k]$$\n    The mean of a binomial distribution $B(N,p)$ is $E[k] = Np$. Therefore, the mean evoked amplitude is:\n    $$\\mu_{EPSC} = Npq$$\n\n2.  **Failure Fraction ($f_0$)**:\n    A failure is an event where zero quanta are released ($k=0$). The probability of a failure, $P_0$, is given by the binomial probability for $k=0$:\n    $$P_0 = P(k=0) = \\binom{N}{0} p^0 (1-p)^{N-0} = (1-p)^N$$\n    The failure fraction, $f_0$, is the experimental estimate of this probability.\n\n3.  **Variance of Evoked EPSC Amplitude ($\\sigma^2_{EPSC}$)**:\n    Since the synaptic current and the noise are independent, their variances add:\n    $$\\sigma^2_{EPSC} = \\text{Var}(I) = \\text{Var}(kq + I_{noise}) = \\text{Var}(kq) + \\text{Var}(I_{noise})$$\n    The variance of the synaptic current is $\\text{Var}(kq) = q^2 \\text{Var}(k)$. The variance of a binomial distribution $B(N,p)$ is $\\text{Var}(k) = Np(1-p)$. The noise variance is given as $\\sigma^2_{noise}$. Thus, the total measured variance is:\n    $$\\sigma^2_{EPSC} = q^2 Np(1-p) + \\sigma^2_{noise}$$\n    This expression relates the total measured variance to the model parameters. The variance arising purely from the synaptic release process is $\\sigma^2_{syn} = \\sigma^2_{EPSC} - \\sigma^2_{noise} = q^2 Np(1-p)$.\n\n**Estimation of Model Parameters ($N$, $p$, $q$)**\n\nWe use the provided experimental data to solve for the parameters $N$, $p$, and $q$.\n- The number of trials is $M = 160$, and the number of failures is $n_{fail} = 10$. The failure fraction is $f_0 = \\frac{n_{fail}}{M} = \\frac{10}{160} = \\frac{1}{16} = 0.0625$.\n- The mean EPSC is $\\mu_{EPSC} = 20\\,\\text{pA}$.\n- The total EPSC variance is $\\sigma^2_{EPSC} = 104\\,\\text{pA}^2$.\n- The noise variance is $\\sigma^2_{noise} = 4\\,\\text{pA}^2$.\n\nFirst, we calculate the variance of the synaptic component of the response by subtracting the noise variance:\n$$\\sigma^2_{syn} = \\sigma^2_{EPSC} - \\sigma^2_{noise} = 104 - 4 = 100\\,\\text{pA}^2$$\nNow we have a system of three equations with our data:\n(i) $20 = Npq$\n(ii) $0.0625 = (1-p)^N$\n(iii) $100 = q^2 Np(1-p)$\n\nTo solve this system, we can use the coefficient of variation (CV) of the synaptic current. The squared CV is:\n$$CV_{syn}^2 = \\frac{\\sigma^2_{syn}}{(\\mu_{EPSC})^2} = \\frac{100}{20^2} = \\frac{100}{400} = 0.25$$\nWe can also express $CV_{syn}^2$ in terms of the model parameters:\n$$CV_{syn}^2 = \\frac{q^2 Np(1-p)}{(Npq)^2} = \\frac{1-p}{Np}$$\nEquating these gives a relationship between $N$ and $p$:\n$$\\frac{1-p}{Np} = 0.25 \\implies 1-p = 0.25 Np \\implies 1 = p(1+0.25N) \\implies p = \\frac{1}{1+0.25N} = \\frac{4}{N+4}$$\nNow, we substitute this expression for $p$ into the failure equation (ii):\n$$0.0625 = (1-p)^N = \\left(1 - \\frac{4}{N+4}\\right)^N = \\left(\\frac{N+4-4}{N+4}\\right)^N = \\left(\\frac{N}{N+4}\\right)^N$$\nWe need to solve the equation $0.0625 = (\\frac{N}{N+4})^N$ for $N$. We can test integer values for $N$, which is a discrete quantity:\n- If $N=1$: $(\\frac{1}{5})^1 = 0.2$\n- If $N=2$: $(\\frac{2}{6})^2 = (\\frac{1}{3})^2 \\approx 0.111$\n- If $N=3$: $(\\frac{3}{7})^3 \\approx 0.0787$\n- If $N=4$: $(\\frac{4}{8})^4 = (\\frac{1}{2})^4 = \\frac{1}{16} = 0.0625$\nThe equation holds exactly for $N=4$. Thus, the estimated number of release sites is $N=4$.\n\nWith $N=4$, we can find the release probability $p$:\n$$p = \\frac{4}{N+4} = \\frac{4}{4+4} = \\frac{4}{8} = 0.5$$\nFinally, we find the quantal size $q$ using the mean equation (i):\n$$q = \\frac{\\mu_{EPSC}}{Np} = \\frac{20}{4 \\times 0.5} = \\frac{20}{2} = 10\\,\\text{pA}$$\nThe estimated parameters are $N=4$, $p=0.5$, and $q=10\\,\\text{pA}$.\n\n**Assessment of Model Consistency**\n\nThe problem asks to use the variance data to assess model consistency. The variance data was central to our estimation of $N$ and $p$ via the coefficient of variation. The consistency of the model can be assessed in two ways.\n\n1.  **Internal Consistency**: The derived parameters ($N=4$, $p=0.5$, $q=10$) must be able to reproduce all the initial measurements.\n    - Mean: $\\mu_{EPSC} = Npq = 4 \\times 0.5 \\times 10 = 20\\,\\text{pA}$. (Matches)\n    - Failure Fraction: $f_0 = (1-p)^N = (1-0.5)^4 = (0.5)^4 = 0.0625$. (Matches)\n    - Total Variance: $\\sigma^2_{EPSC} = q^2 Np(1-p) + \\sigma^2_{noise} = 10^2 \\times 4 \\times 0.5 \\times (1-0.5) + 4 = 100 \\times 1 + 4 = 104\\,\\text{pA}^2$. (Matches)\n    The fact that an integer solution for $N$ exists that perfectly satisfies the equations for the mean, variance, and failure rate indicates that the data are internally consistent with the simple binomial model.\n\n2.  **External Consistency**: The model's predictions can be compared with independent measurements. The problem provides that asynchronous quantal events, measured in a separate strontium-substitution experiment, have a mean amplitude of $q_{async} = 10\\,\\text{pA}$. This experiment provides a direct and independent measurement of the quantal size $q$. Our estimate, derived from the statistics of synchronous release, is $q=10\\,\\text{pA}$. The perfect agreement between the indirectly estimated $q$ and the directly measured $q_{async}$ provides strong evidence supporting the validity of the binomial model for this synapse under the given assumptions.\n\nIn summary, the binomial model is highly consistent with all available measurements. The estimated parameters are $N=4$ release sites, a release probability $p=0.5$, and a quantal size $q=10\\,\\text{pA}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix} 4 & 0.5 & 10 \\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Building on the principles of synaptic transmission , a core task in psychopharmacology is to understand how drugs modulate this process at the molecular level. This practice focuses on the sophisticated mechanism of partial agonism, using the clinically vital example of the antipsychotic aripiprazole. By applying receptor theory, you will calculate how a drug’s intrinsic efficacy directly determines its signaling output, clarifying its role as a \"dopamine stabilizer.\"",
            "id": "4731545",
            "problem": "In psychiatry-relevant neurophysiology, the Dopamine D2 receptor is a G protein-coupled receptor (GPCR) that couples predominantly to the inhibitory G proteins of the Gi/o family, reducing cyclic adenosine monophosphate (cAMP) formation when active. Aripiprazole is clinically described as a partial agonist at D2 receptors. Starting from the classical single-site Hill-Langmuir binding framework with Hill coefficient $n=1$ and the fundamental definition that macroscopic signaling output scales linearly with the number of occupied receptors and the ligand-specific intrinsic efficacy, explain mechanistically what partial agonism means at the D2 receptor for aripiprazole. Then, compute the expected receptor signaling output ratio of aripiprazole to a full agonist at matched fractional occupancy.\n\nAssume a receptor population of $R_{T} = 1.0 \\times 10^{6}$ receptors per cell and a linear coupling constant $k = 1.0 \\times 10^{-6}$ signaling units per occupied receptor. Let the intrinsic efficacy of aripiprazole be $\\alpha_{\\text{ari}} = 0.32$ and the intrinsic efficacy of the full agonist (dopamine) be $\\alpha_{\\text{DA}} = 1.00$. Consider concentrations chosen to produce the same fractional occupancy under single-site binding: $[L]_{\\text{ari}} = 6\\,\\text{nM}$ with $K_{D,\\text{ari}} = 3\\,\\text{nM}$ for aripiprazole, and $[L]_{\\text{DA}} = 20\\,\\text{nM}$ with $K_{D,\\text{DA}} = 10\\,\\text{nM}$ for dopamine.\n\nUsing these values and the above first-principles framework, derive the signaling outputs and report the ratio $S_{\\text{ari}}/S_{\\text{DA}}$. Express your final answer as a unitless decimal rounded to four significant figures.",
            "solution": "The problem as stated is scientifically grounded, well-posed, objective, and internally consistent. It presents a standard pharmacological calculation based on receptor theory, applying the concepts of fractional occupancy and intrinsic efficacy to the partial agonist aripiprazole. All necessary parameters are provided to solve the problem. The problem is therefore deemed valid and a solution will be provided.\n\nThe Dopamine D2 receptor is a G protein-coupled receptor (GPCR) that, upon activation, engages Gi/o proteins to inhibit adenylyl cyclase, thereby reducing cyclic adenosine monophosphate (cAMP) levels. In receptor theory, a ligand’s effect is determined by two separable properties: its affinity, quantified by the dissociation constant $K_{D}$, and its efficacy, quantified by an intrinsic efficacy parameter $\\alpha$ relative to a reference full agonist with $\\alpha = 1$. A partial agonist is defined by $\\alpha < 1$. This means that even when occupying the same fraction of receptors as a full agonist, the partial agonist stabilizes the receptor in a signaling-active conformation that is less efficient at coupling to downstream effectors, producing a lower maximal signaling output.\n\nWe start from two foundational definitions:\n\n1. Under the single-site Hill-Langmuir binding model with Hill coefficient $n=1$, the fractional occupancy is\n$$\n\\theta \\;=\\; \\frac{[L]}{K_{D} + [L]} \\, .\n$$\n\n2. Under a linear transduction assumption with negligible receptor reserve and negligible basal activity, the macroscopic signaling output $S$ scales with the number of occupied receptors and the ligand-specific intrinsic efficacy:\n$$\nS \\;=\\; k \\,\\alpha \\, R_{\\text{occ}} \\;=\\; k \\,\\alpha \\, \\theta \\, R_{T} \\, ,\n$$\nwhere $R_{\\text{occ}} = \\theta R_{T}$ is the number of occupied receptors, $R_{T}$ is the total receptor population, $k$ is a coupling constant converting occupied receptors into signaling units, and $\\alpha$ is the intrinsic efficacy of the ligand.\n\nWe are given $R_{T} = 1.0 \\times 10^{6}$ receptors per cell and $k = 1.0 \\times 10^{-6}$ signaling units per occupied receptor. We also have $\\alpha_{\\text{ari}} = 0.32$ for aripiprazole and $\\alpha_{\\text{DA}} = 1.00$ for dopamine. The chosen concentrations are $[L]_{\\text{ari}} = 6\\,\\text{nM}$ with $K_{D,\\text{ari}} = 3\\,\\text{nM}$, and $[L]_{\\text{DA}} = 20\\,\\text{nM}$ with $K_{D,\\text{DA}} = 10\\,\\text{nM}$.\n\nFirst, compute fractional occupancies:\n\n- For aripiprazole,\n$$\n\\theta_{\\text{ari}} \\;=\\; \\frac{[L]_{\\text{ari}}}{K_{D,\\text{ari}} + [L]_{\\text{ari}}} \\;=\\; \\frac{6}{3 + 6} \\;=\\; \\frac{6}{9} \\;=\\; \\frac{2}{3} \\, .\n$$\n\n- For dopamine,\n$$\n\\theta_{\\text{DA}} \\;=\\; \\frac{[L]_{\\text{DA}}}{K_{D,\\text{DA}} + [L]_{\\text{DA}}} \\;=\\; \\frac{20}{10 + 20} \\;=\\; \\frac{20}{30} \\;=\\; \\frac{2}{3} \\, .\n$$\n\nThus, the fractional occupancies match: $\\theta_{\\text{ari}} = \\theta_{\\text{DA}} = \\frac{2}{3}$.\n\nNext, compute signaling outputs using $S = k \\alpha \\theta R_{T}$. Note that $k R_{T} = \\left(1.0 \\times 10^{-6}\\right)\\left(1.0 \\times 10^{6}\\right) = 1$.\n\n- For aripiprazole,\n$$\nS_{\\text{ari}} \\;=\\; k \\,\\alpha_{\\text{ari}} \\,\\theta_{\\text{ari}} \\, R_{T} \\;=\\; 1 \\times 0.32 \\times \\frac{2}{3} \\;=\\; \\frac{0.64}{3} \\;=\\; 0.213\\overline{3} \\, .\n$$\n\n- For dopamine,\n$$\nS_{\\text{DA}} \\;=\\; k \\,\\alpha_{\\text{DA}} \\,\\theta_{\\text{DA}} \\, R_{T} \\;=\\; 1 \\times 1.00 \\times \\frac{2}{3} \\;=\\; \\frac{2}{3} \\;=\\; 0.6\\overline{6} \\, .\n$$\n\nFinally, compute the ratio:\n$$\n\\frac{S_{\\text{ari}}}{S_{\\text{DA}}} \\;=\\; \\frac{k \\,\\alpha_{\\text{ari}} \\,\\theta \\, R_{T}}{k \\,\\alpha_{\\text{DA}} \\,\\theta \\, R_{T}} \\;=\\; \\frac{\\alpha_{\\text{ari}}}{\\alpha_{\\text{DA}}} \\;=\\; \\frac{0.32}{1.00} \\;=\\; 0.32 \\, .\n$$\n\nRounded to four significant figures, this ratio is $0.3200$. This result embodies the core mechanistic meaning of partial agonism: at the same fractional occupancy, a partial agonist yields a proportionally lower signaling output determined by its intrinsic efficacy $\\alpha$ relative to a full agonist.",
            "answer": "$$\\boxed{0.3200}$$"
        },
        {
            "introduction": "Psychiatric research increasingly uses neuroimaging to identify systems-level biomarkers of illness, linking brain structure to function and behavior. This problem connects the cellular world of axons to the macroscopic analysis of brain connectivity using Diffusion Tensor Imaging (DTI). You will derive and apply the formula for Fractional Anisotropy ($FA$), a key metric of white matter integrity, to understand how alterations in structural pathways like the fronto-limbic tracts are quantified and interpreted in disorders such as depression.",
            "id": "4731622",
            "problem": "A diffusion tensor imaging (DTI) assessment of the uncinate fasciculus, a fronto-limbic tract connecting the ventromedial prefrontal cortex and the amygdala, was performed in one individual with major depressive disorder and one matched healthy control. In DTI, the diffusion tensor is a real, symmetric, positive semidefinite matrix whose eigenvalues $\\,\\lambda_1, \\lambda_2, \\lambda_3\\,$ represent principal diffusivities along orthogonal axes. The mean diffusivity is defined as $\\,\\bar{\\lambda} = (\\lambda_1+\\lambda_2+\\lambda_3)/3\\,$. Consider the unscaled anisotropy measure $\\,A = \\frac{\\sqrt{(\\lambda_1-\\bar{\\lambda})^2+(\\lambda_2-\\bar{\\lambda})^2+(\\lambda_3-\\bar{\\lambda})^2}}{\\sqrt{\\lambda_1^2+\\lambda_2^2+\\lambda_3^2}}\\,.$ Fractional Anisotropy (FA) is defined as $\\,\\mathrm{FA} = k \\, A\\,$, where the scale factor $\\,k\\,$ is chosen so that $\\,0 \\le \\mathrm{FA} \\le 1\\,$ and $\\,\\mathrm{FA} = 1\\,$ for perfectly uniaxial diffusion (that is, $\\,\\lambda_1 > 0\\,$ and $\\,\\lambda_2=\\lambda_3=0\\,$).\n\n1. Using the above definitions and the uniaxial diffusion requirement, derive the closed-form expression for $\\,k\\,$ and hence $\\,\\mathrm{FA}\\,$ in terms of $\\,\\lambda_1, \\lambda_2, \\lambda_3\\,$.\n2. The measured eigenvalues (in $\\mathrm{mm}^2/\\mathrm{s}$) for the patient are $\\,\\lambda_1 = 1.60 \\times 10^{-3}\\,$, $\\,\\lambda_2 = 0.90 \\times 10^{-3}\\,$, $\\,\\lambda_3 = 0.85 \\times 10^{-3}\\,$, and for the control are $\\,\\lambda_1 = 1.80 \\times 10^{-3}\\,$, $\\,\\lambda_2 = 0.50 \\times 10^{-3}\\,$, $\\,\\lambda_3 = 0.45 \\times 10^{-3}\\,$. Compute $\\,\\mathrm{FA}\\,$ for both the patient and the control based on your derived expression.\n3. Report the patient-to-control $\\,\\mathrm{FA}\\,$ ratio. Round your final ratio to four significant figures. Express the ratio as a dimensionless number.\n\nBriefly, in your reasoning, ground any interpretation of the computed values in neuroanatomical and neurophysiological principles relevant to psychiatry, focusing on fronto-limbic white matter integrity, but ensure the final reported answer is only the requested numerical ratio.",
            "solution": "The problem as stated is scientifically grounded, well-posed, objective, and internally consistent. It provides standard definitions from the field of diffusion tensor imaging (DTI) and asks for a derivation and calculation based on these definitions. All necessary data are provided. The problem is therefore deemed valid and a solution will be provided.\n\nThe solution is presented in three parts as requested by the problem statement.\n\nPart 1: Derivation of the scaling factor $k$ and the expression for Fractional Anisotropy ($\\mathrm{FA}$).\n\nThe problem defines the following quantities:\nThe eigenvalues of the diffusion tensor: $\\lambda_1, \\lambda_2, \\lambda_3$.\nThe mean diffusivity:\n$$ \\bar{\\lambda} = \\frac{\\lambda_1+\\lambda_2+\\lambda_3}{3} $$\nThe unscaled anisotropy measure:\n$$ A = \\frac{\\sqrt{(\\lambda_1-\\bar{\\lambda})^2+(\\lambda_2-\\bar{\\lambda})^2+(\\lambda_3-\\bar{\\lambda})^2}}{\\sqrt{\\lambda_1^2+\\lambda_2^2+\\lambda_3^2}} $$\nThe Fractional Anisotropy ($\\mathrm{FA}$):\n$$ \\mathrm{FA} = k \\, A $$\nThe scaling factor $k$ is determined by the condition that $\\mathrm{FA} = 1$ for the case of perfectly uniaxial diffusion, which is defined by $\\lambda_1 > 0$ and $\\lambda_2=\\lambda_3=0$.\n\nWe will now calculate the value of $A$ for the uniaxial case.\nFirst, we find the mean diffusivity $\\bar{\\lambda}$ under these conditions:\n$$ \\bar{\\lambda}_{\\text{uniaxial}} = \\frac{\\lambda_1 + 0 + 0}{3} = \\frac{\\lambda_1}{3} $$\nNext, we substitute this into the expression for the numerator of $A$:\n$$ \\text{Numerator} = \\sqrt{\\left(\\lambda_1-\\frac{\\lambda_1}{3}\\right)^2+\\left(0-\\frac{\\lambda_1}{3}\\right)^2+\\left(0-\\frac{\\lambda_1}{3}\\right)^2} $$\n$$ = \\sqrt{\\left(\\frac{2\\lambda_1}{3}\\right)^2+\\left(-\\frac{\\lambda_1}{3}\\right)^2+\\left(-\\frac{\\lambda_1}{3}\\right)^2} $$\n$$ = \\sqrt{\\frac{4\\lambda_1^2}{9}+\\frac{\\lambda_1^2}{9}+\\frac{\\lambda_1^2}{9}} = \\sqrt{\\frac{6\\lambda_1^2}{9}} = \\lambda_1 \\sqrt{\\frac{2}{3}} $$\nsince $\\lambda_1 > 0$.\n\nNow, we calculate the denominator of $A$ for the uniaxial case:\n$$ \\text{Denominator} = \\sqrt{\\lambda_1^2+0^2+0^2} = \\sqrt{\\lambda_1^2} = \\lambda_1 $$\nCombining these, the value of $A$ for uniaxial diffusion, denoted $A_{\\text{uniaxial}}$, is:\n$$ A_{\\text{uniaxial}} = \\frac{\\lambda_1 \\sqrt{\\frac{2}{3}}}{\\lambda_1} = \\sqrt{\\frac{2}{3}} $$\nThe condition $\\mathrm{FA}=1$ for this case gives:\n$$ 1 = k \\cdot A_{\\text{uniaxial}} = k \\sqrt{\\frac{2}{3}} $$\nSolving for $k$, we find the scaling factor:\n$$ k = \\frac{1}{\\sqrt{2/3}} = \\sqrt{\\frac{3}{2}} $$\nThus, the closed-form expression for Fractional Anisotropy is:\n$$ \\mathrm{FA} = \\sqrt{\\frac{3}{2}} \\frac{\\sqrt{(\\lambda_1-\\bar{\\lambda})^2+(\\lambda_2-\\bar{\\lambda})^2+(\\lambda_3-\\bar{\\lambda})^2}}{\\sqrt{\\lambda_1^2+\\lambda_2^2+\\lambda_3^2}} $$\nwhere $\\bar{\\lambda} = \\frac{\\lambda_1+\\lambda_2+\\lambda_3}{3}$. This is the standard definition of $\\mathrm{FA}$.\n\nPart 2: Computation of $\\mathrm{FA}$ for the patient and the control.\n\nThe value of $\\mathrm{FA}$ is a dimensionless ratio. The units of the eigenvalues ($\\mathrm{mm}^2/\\mathrm{s}$) and the common scaling factor of $10^{-3}$ will cancel out in the calculation. We can therefore perform the calculation using the given numerical coefficients.\n\nFor the patient (P):\nThe eigenvalues are $\\lambda_{1,P} = 1.60 \\times 10^{-3}$, $\\lambda_{2,P} = 0.90 \\times 10^{-3}$, and $\\lambda_{3,P} = 0.85 \\times 10^{-3}$. We use the coefficients $\\lambda_1=1.60$, $\\lambda_2=0.90$, $\\lambda_3=0.85$.\nThe mean diffusivity is:\n$$ \\bar{\\lambda}_P = \\frac{1.60+0.90+0.85}{3} = \\frac{3.35}{3} $$\nThe sum of squared differences from the mean is:\n$$ \\sum_{i=1}^{3} (\\lambda_{i,P}-\\bar{\\lambda}_P)^2 = \\left(1.60-\\frac{3.35}{3}\\right)^2 + \\left(0.90-\\frac{3.35}{3}\\right)^2 + \\left(0.85-\\frac{3.35}{3}\\right)^2 $$\n$$ = \\left(\\frac{4.80-3.35}{3}\\right)^2 + \\left(\\frac{2.70-3.35}{3}\\right)^2 + \\left(\\frac{2.55-3.35}{3}\\right)^2 $$\n$$ = \\left(\\frac{1.45}{3}\\right)^2 + \\left(\\frac{-0.65}{3}\\right)^2 + \\left(\\frac{-0.80}{3}\\right)^2 = \\frac{1}{9}(2.1025 + 0.4225 + 0.6400) = \\frac{3.165}{9} $$\nThe sum of squares of the eigenvalues is:\n$$ \\sum_{i=1}^{3} \\lambda_{i,P}^2 = 1.60^2 + 0.90^2 + 0.85^2 = 2.56 + 0.81 + 0.7225 = 4.0925 $$\nNow, we compute $\\mathrm{FA}_P$:\n$$ \\mathrm{FA}_P = \\sqrt{\\frac{3}{2}} \\frac{\\sqrt{3.165/9}}{\\sqrt{4.0925}} = \\sqrt{\\frac{3}{2} \\cdot \\frac{3.165}{9 \\cdot 4.0925}} = \\sqrt{\\frac{3.165}{6 \\cdot 4.0925}} = \\sqrt{\\frac{3.165}{24.555}} \\approx 0.35899 $$\n\nFor the control (C):\nThe eigenvalues are $\\lambda_{1,C} = 1.80 \\times 10^{-3}$, $\\lambda_{2,C} = 0.50 \\times 10^{-3}$, and $\\lambda_{3,C} = 0.45 \\times 10^{-3}$. We use the coefficients $\\lambda_1=1.80$, $\\lambda_2=0.50$, $\\lambda_3=0.45$.\nThe mean diffusivity is:\n$$ \\bar{\\lambda}_C = \\frac{1.80+0.50+0.45}{3} = \\frac{2.75}{3} $$\nThe sum of squared differences from the mean is:\n$$ \\sum_{i=1}^{3} (\\lambda_{i,C}-\\bar{\\lambda}_C)^2 = \\left(1.80-\\frac{2.75}{3}\\right)^2 + \\left(0.50-\\frac{2.75}{3}\\right)^2 + \\left(0.45-\\frac{2.75}{3}\\right)^2 $$\n$$ = \\left(\\frac{5.40-2.75}{3}\\right)^2 + \\left(\\frac{1.50-2.75}{3}\\right)^2 + \\left(\\frac{1.35-2.75}{3}\\right)^2 $$\n$$ = \\left(\\frac{2.65}{3}\\right)^2 + \\left(\\frac{-1.25}{3}\\right)^2 + \\left(\\frac{-1.40}{3}\\right)^2 = \\frac{1}{9}(7.0225 + 1.5625 + 1.9600) = \\frac{10.545}{9} $$\nThe sum of squares of the eigenvalues is:\n$$ \\sum_{i=1}^{3} \\lambda_{i,C}^2 = 1.80^2 + 0.50^2 + 0.45^2 = 3.24 + 0.25 + 0.2025 = 3.6925 $$\nNow, we compute $\\mathrm{FA}_C$:\n$$ \\mathrm{FA}_C = \\sqrt{\\frac{3}{2}} \\frac{\\sqrt{10.545/9}}{\\sqrt{3.6925}} = \\sqrt{\\frac{3}{2} \\cdot \\frac{10.545}{9 \\cdot 3.6925}} = \\sqrt{\\frac{10.545}{6 \\cdot 3.6925}} = \\sqrt{\\frac{10.545}{22.155}} \\approx 0.68990 $$\n\nBrief Interpretation: The computed $\\mathrm{FA}$ value for the patient ($\\mathrm{FA}_P \\approx 0.36$) is substantially lower than that for the healthy control ($\\mathrm{FA}_C \\approx 0.69$). Fractional Anisotropy is a measure of white matter microstructural integrity. A higher $\\mathrm{FA}$ value indicates more directional coherence of water diffusion, which reflects highly organized and myelinated axonal tracts. A lower $\\mathrm{FA}$ suggests reduced integrity, which may arise from demyelination, axonal damage, or less coherent fiber organization. The uncinate fasciculus connects the ventromedial prefrontal cortex and the amygdala, forming a critical part of the brain's emotion regulation circuitry. The observed lower $\\mathrm{FA}$ in the patient with major depressive disorder is consistent with a widely reported finding in psychiatric neuroimaging, suggesting that compromised structural connectivity in this fronto-limbic pathway may be a neurobiological substrate for deficits in emotion regulation characteristic of depression.\n\nPart 3: Patient-to-control $\\mathrm{FA}$ ratio.\n\nThe final step is to compute the ratio of the patient's $\\mathrm{FA}$ to the control's $\\mathrm{FA}$ and round the result to four significant figures.\n$$ \\text{Ratio} = \\frac{\\mathrm{FA}_P}{\\mathrm{FA}_C} = \\frac{0.35899...}{0.68990...} \\approx 0.52035... $$\nRounding to four significant figures, the ratio is $0.5204$.",
            "answer": "$$\n\\boxed{0.5204}\n$$"
        }
    ]
}